@article{Godman_B-2021_26984,
title = {Health authority activities to enhance the quality and efficiency of medicine use and their impact},
author = {Godman, B.},
month = {feb},
year = {2021},
abstract = {In the previous commentary paper, we discussed the growing expenditure on medicines due to the continued launch of new premium priced medicines, especially for oncology and orphan diseases, growth in non-communicable diseases (NCDs) assisted by aging populations with associated increased use of medicines as well as changing clinical guidelines.[1-5] As a result, global sales of medicines are likely to exceed $1.5 trillion by 2023, with compounded annual growth rates estimated at 3 to 6% per annum.[6] This is a concern not only for high income countries struggling to fund new premium priced medicines for cancer and orphan diseases but also for lower- and middle-income countries (LMICs) where expenditure on medicines can account for over 60% of total healthcare expenditure affecting key issues such as access and affordability.[7-9] There are also concerns how governments can attain or retain universal healthcare given ongoing pressures on available resources, enhanced by the COVID-19 pandemic and its unintended consequences, and concomitantly strive to reduce morbidity and mortality of NCDs as part of agreed Sustainable Development Goals (SDGs).[10-13] In addition, address concerns with rising rates of antimicrobial resistance (AMR) increasing morbidity, mortality, and costs, as a result of inappropriate prescribing and dispensing of antibiotics especially in ambulatory care},
pages = {11-16},
volume = {11},
issue = {1},
journal = {Advances in Human Biology},
publisher = {Wolters Kluwer},
url = {https://doi.org/10.4103/2321-8568.308858},
}
